Jeffrey William Henderson
CIK: 0001324015
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (18 total)
- May 5, 2026HALO
HALOZYME THERAPEUTICS, INC.
Award(A)Direct3.8K shares- - Mar 17, 2026QCOM
QUALCOMM INC/DE
Award(A)Direct2.6K shares- - Mar 8, 2026QCOM
QUALCOMM INC/DE
Disposition(D)Direct759 shares at avg. $135.69$103K - Mar 8, 2026QCOM
QUALCOMM INC/DE
Exercise(M)Direct2.4K shares- - Jan 27, 2026BDX
BECTON DICKINSON & CO
Award(A)Direct1.1K shares- - May 1, 2025HALO
HALOZYME THERAPEUTICS, INC.
Award(A)Direct4.2K shares- - Apr 28, 2025HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct4.3K shares at avg. $60.34$259K - Apr 28, 2025HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct200 shares at avg. $60.99$12K - Apr 1, 2025HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct503 shares at avg. $64.05$32K - Mar 18, 2025QCOM
QUALCOMM INC/DE
Award(A)Direct2.1K shares- - Mar 9, 2025QCOM
QUALCOMM INC/DE
Exercise(M)Direct1.9K shares- - Mar 3, 2025HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct3.2K shares at avg. $59.12$189K - Mar 3, 2025HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct1.8K shares at avg. $57.93$104K - Feb 10, 2025BDX
BECTON DICKINSON & CO
Purchase(P)Direct1.5K shares at avg. $233.62$350K - Feb 3, 2025HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct3.9K shares at avg. $56.41$220K - Feb 3, 2025HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct1.1K shares at avg. $55.94$62K - Jan 28, 2025BDX
BECTON DICKINSON & CO
Award(A)Direct930 shares- - Jan 6, 2025HALO
HALOZYME THERAPEUTICS, INC.
Sale(S)Direct10K shares at avg. $50.01$500K
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 5, 2026 |  HALO HALOZYME THERAPEUTICS, INC. | Award(A) | 3,796 | - | $0 | Direct |
| Mar 17, 2026 |  QCOM QUALCOMM INC/DE | Award(A) | 2,563 | - | $0 | Direct |
| Mar 8, 2026 | QCOM QUALCOMM INC/DE | Disposition(D) | 759 | $135.69 | $102,989 | Direct |
| Mar 8, 2026 | QCOM QUALCOMM INC/DE | Exercise(M) | 2,355 | - | $0 | Direct |
| Jan 27, 2026 |  BDX BECTON DICKINSON & CO | Award(A) | 1,098 | - | $0 | Direct |
| May 1, 2025 | HALO HALOZYME THERAPEUTICS, INC. | Award(A) | 4,165 | - | - | Direct |
| Apr 28, 2025 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 4,297 | $60.34 | $259,268 | Direct |
| Apr 28, 2025 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 200 | $60.99 | $12,199 | Direct |
| Apr 1, 2025 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 503 | $64.05 | $32,217 | Direct |
| Mar 18, 2025 | QCOM QUALCOMM INC/DE | Award(A) | 2,097 | - | - | Direct |
| Mar 9, 2025 | QCOM QUALCOMM INC/DE | Exercise(M) | 1,901 | - | - | Direct |
| Mar 3, 2025 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 3,205 | $59.12 | $189,467 | Direct |
| Mar 3, 2025 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 1,795 | $57.93 | $103,992 | Direct |
| Feb 10, 2025 | BDX BECTON DICKINSON & CO | Purchase(P) | 1,500 | $233.62 | $350,430 | Direct |
| Feb 3, 2025 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 3,900 | $56.41 | $219,980 | Direct |
| Feb 3, 2025 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 1,100 | $55.94 | $61,537 | Direct |
| Jan 28, 2025 | BDX BECTON DICKINSON & CO | Award(A) | 930 | - | $0 | Direct |
| Jan 6, 2025 | HALO HALOZYME THERAPEUTICS, INC. | Sale(S) | 10,000 | $50.01 | $500,060 | Direct |
1-18 of 18 transactions
About Henderson Jeffrey William
Henderson Jeffrey William (SEC CIK 0001324015) files insider reports with the SEC as Director of HALOZYME THERAPEUTICS, INC. (HALO), Director of QUALCOMM INC/DE (QCOM) and Director of BECTON DICKINSON & CO (BDX).
Signal8 holds 14 ownership filings by Henderson Jeffrey William, all Form 4s, filed between Jan 7, 2025 and May 7, 2026. Those filings report 18 transactions, from Jan 6, 2025 to May 5, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Henderson Jeffrey William's filings is in SAN DIEGO, CA.
Recent filings by Henderson Jeffrey William
- May 5, 2026: Grant or award of HALO shares (Form 4, code A).
- Mar 17, 2026: Grant or award of QCOM shares (Form 4, code A).
- Mar 8, 2026: Disposition to issuer transaction of QCOM shares (Form 4, code D).
- Mar 8, 2026: Option exercise of QCOM shares (Form 4, code M).
- Jan 27, 2026: Grant or award of BDX shares (Form 4, code A).
Other insiders filing for HALOZYME THERAPEUTICS, INC. (HALO)
- Torley Helen, PRESIDENT AND CEO
- Connaughton Bernadette, Director
- Daly James M, Director
- Posard Matthew L., Director
- Appelhans Dannielle, Director
- RAMSAY DAVID A, EVP, PRESIDENT, DRUG DELIVERY